{"gene":"ETV6","run_date":"2026-04-28T17:46:03","timeline":{"discoveries":[{"year":1997,"finding":"TEL (ETV6) protein products are nuclear phosphoproteins that display specific DNA-binding activity toward classical ETS binding sites; two isoforms of 50 kDa and 57 kDa are produced by translation initiation at either of the two first in-frame ATGs (codon 1 and 43), and both are modified by multiple phosphorylation events in vivo.","method":"Western blot, immunofluorescence, EMSA, murine TEL cDNA isolation","journal":"Oncogene","confidence":"High","confidence_rationale":"Tier 2 — direct biochemical characterization with multiple orthogonal methods (Western, immunofluorescence, EMSA)","pmids":["9018121"],"is_preprint":false},{"year":1997,"finding":"The TEL-JAK2 fusion protein, generated by t(9;12)(p24;p13), includes the TEL oligomerization (pointed/HLH) domain fused to the JAK2 catalytic domain; TEL-induced oligomerization results in constitutive tyrosine kinase activity and confers cytokine-independent proliferation to Ba/F3 cells.","method":"Characterization of t(9;12) translocation product, in vitro kinase assay, Ba/F3 growth factor independence assay","journal":"Science","confidence":"High","confidence_rationale":"Tier 1-2 — original discovery with biochemical kinase activation assay and functional cell transformation, replicated in subsequent work","pmids":["9360930"],"is_preprint":false},{"year":1998,"finding":"The ETV6-NTRK3 fusion gene, arising from t(12;15)(p13;q25) in congenital fibrosarcoma, encodes a chimeric protein containing the ETV6 helix-loop-helix (HLH) dimerization domain fused to the NTRK3 protein tyrosine kinase domain, producing a constitutively active chimeric tyrosine kinase.","method":"Cloning of chromosomal breakpoints, RT-PCR, sequencing of fusion transcripts","journal":"Nature genetics","confidence":"High","confidence_rationale":"Tier 1-2 — original cloning and molecular characterization of fusion gene structure, widely replicated","pmids":["9462753"],"is_preprint":false},{"year":1998,"finding":"TEL (ETV6) is required specifically for hematopoiesis in the bone marrow; TEL-/- hematopoietic cells can populate yolk sac and fetal liver but fail to establish bone marrow hematopoiesis, establishing TEL as the first transcription factor specifically required for bone marrow hematopoietic activity.","method":"Gene targeting in mice, chimera generation with TEL-/- ES cells, lineage analysis","journal":"Genes & development","confidence":"High","confidence_rationale":"Tier 2 — clean knockout with defined cellular phenotype, rigorous in vivo model","pmids":["9694803"],"is_preprint":false},{"year":1999,"finding":"The TEL pointed (HLH) domain functions as a portable transcriptional repression motif; the TEL-AML1 fusion protein and wild-type TEL both bind the mSin3A corepressor via the pointed domain, and AML1B also contributes an mSin3-interaction domain to the fusion protein, making the complex bind mSin3A more stably than either alone.","method":"GAL4 reporter assays, deletion mutagenesis, co-immunoprecipitation","journal":"Molecular and cellular biology","confidence":"High","confidence_rationale":"Tier 1-2 — reconstitution-level reporter assay plus co-IP, multiple domains tested","pmids":["10490596"],"is_preprint":false},{"year":1999,"finding":"TEL (ETV6) functions as a transcriptional repressor by recruiting two distinct corepressor complexes: the central region of TEL recruits SMRT and mSin3A, while the HLH domain represses transcription through a corepressor-independent mechanism.","method":"GAL4 reporter assay, co-immunoprecipitation, deletion mutagenesis","journal":"Biochemical and biophysical research communications","confidence":"High","confidence_rationale":"Tier 1-2 — multiple orthogonal methods, two distinct repression mechanisms identified","pmids":["10544023"],"is_preprint":false},{"year":1999,"finding":"UBC9 (a SUMO E2-conjugating enzyme) physically interacts with TEL specifically through its HLH domain in vitro and in vivo, and co-expression of UBC9 restores promoter activity repressed by TEL without inducing TEL degradation, indicating UBC9 modulates TEL transcriptional repressor activity.","method":"In vivo interaction assay (two-hybrid equivalent), co-immunoprecipitation, GAL4 reporter assay, mutagenesis of UBC9 catalytic residues","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 1-2 — multiple orthogonal methods including mutagenesis and functional reporter","pmids":["10377438"],"is_preprint":false},{"year":1999,"finding":"ETV6 (TEL) represses the MCSFR proximal promoter in a DNA-binding-dependent manner, requiring the ETS DNA-binding domain; deletion of the HLH region reduces but does not abolish repression, and inhibition requires interaction with other promoter-bound proteins such as CBFA2B and C/EBPα.","method":"Reporter gene (luciferase) assays, deletion/mutational analysis of ETV6 and MCSFR promoter","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"Medium","confidence_rationale":"Tier 1 — in vitro reporter assay with mutagenesis; single study","pmids":["9050885"],"is_preprint":false},{"year":2000,"finding":"TEL (ETV6) recruits the nuclear receptor corepressor N-CoR through its central region, and this interaction is required for full transcriptional repression; TEL-AML1 fusion also binds N-CoR via the TEL central region retained in the fusion.","method":"Co-immunoprecipitation, deletion mutagenesis, reporter assays","journal":"Blood","confidence":"High","confidence_rationale":"Tier 1-2 — co-IP plus functional reporter assay with domain mapping","pmids":["11001911"],"is_preprint":false},{"year":2000,"finding":"Fusion proteins containing the TEL oligomerization (pointed) domain fused to the kinase domains of JAK1, JAK2, JAK3, or TYK2 all confer cytokine-independent growth to Ba/F3 cells; STAT5 is the principal activated STAT in TEL-JAK2 and TEL-JAK1 cells, and a dominant-negative STAT5A blocks cytokine independence; TEL-JAK3 and TEL-TYK2 additionally activate STAT1 and STAT3.","method":"Ba/F3 growth factor independence assay, EMSA, dominant-negative STAT5 expression, gene expression analysis","journal":"Blood","confidence":"High","confidence_rationale":"Tier 1-2 — reconstitution in hematopoietic cells, multiple JAK fusions tested, dominant-negative rescue","pmids":["10706877"],"is_preprint":false},{"year":2000,"finding":"TEL overexpression induces a G1 cell cycle arrest in multiple cell types and suppresses Ras-mediated transformation (colony formation in soft agar, tumor formation in nude mice); both the pointed domain and DNA-binding domain of TEL are required for these tumor suppressor phenotypes.","method":"Cell proliferation assays, soft agar colony assay, nude mouse tumor assay, TEL domain mutagenesis","journal":"Oncogene","confidence":"High","confidence_rationale":"Tier 2 — multiple orthogonal in vitro and in vivo assays with domain mapping","pmids":["11077441"],"is_preprint":false},{"year":2000,"finding":"TEL-JAK2 transgenic mice develop fatal T-cell leukemia with selective expansion of CD8+ T cells; the TEL-JAK2 protein is tyrosine-phosphorylated in leukemic tissue and activates STAT1 and STAT5 in vivo.","method":"Transgenic mouse model, flow cytometry, Western blot/phospho-analysis, TCR clonality analysis","journal":"Blood","confidence":"High","confidence_rationale":"Tier 2 — in vivo transgenic model with biochemical STAT activation data","pmids":["10845925"],"is_preprint":false},{"year":2001,"finding":"TEL repression requires both the N-terminal pointed domain (which binds mSin3A) and a central repression domain (amino acids 268-303, which binds N-CoR); HDAC3, but not other HDACs, directly associates with the central region of TEL independently of N-CoR, and HDAC inhibition with trichostatin A impairs TEL-dependent repression and reverses TEL-induced cellular aggregation.","method":"Deletion mutagenesis, co-immunoprecipitation, ChIP (histone H3 acetylation at stromelysin-1 promoter), TSA treatment, reporter assay","journal":"Oncogene","confidence":"High","confidence_rationale":"Tier 1-2 — ChIP plus co-IP plus functional pharmacological inhibition, multiple orthogonal methods","pmids":["11439334"],"is_preprint":false},{"year":2002,"finding":"ETV6-NTRK3 chimeric tyrosine kinase transforms murine mammary epithelial cells and forms tumors in nude mice that express epithelial antigens, establishing ETV6-NTRK3 as a dominantly acting oncogene in breast epithelial transformation; this fusion is present in 92% of human secretory breast carcinomas.","method":"Retroviral gene transfer, nude mouse tumor assay, immunohistochemistry, RT-PCR of patient tumors","journal":"Cancer cell","confidence":"High","confidence_rationale":"Tier 2 — functional transformation assay in primary epithelial cells plus in vivo tumor formation","pmids":["12450792"],"is_preprint":false},{"year":2002,"finding":"TEL-Abl (ETV6-ABL1) fusion requires the TEL pointed domain oligomerization and ABL tyrosine kinase activity to induce myeloproliferative disease in mice; the fusion transforms multipotent hematopoietic progenitors capable of multilineage repopulation.","method":"Retroviral bone marrow transduction-transplantation model, domain mutagenesis, multilineage repopulation assays","journal":"Blood","confidence":"High","confidence_rationale":"Tier 2 — in vivo mouse model with domain mutagenesis and progenitor characterization","pmids":["12036890"],"is_preprint":false},{"year":2002,"finding":"p38 MAP kinase directly phosphorylates TEL in vitro and in vivo at Ser22 (constitutive) and Ser257 (inducible); TEL binds p38 physically, and p38-dependent phosphorylation reduces TEL trans-repressional activity at ETS-binding sites.","method":"In vivo phosphorylation assay, in vitro kinase assay, reporter assay, co-immunoprecipitation, site-directed mutagenesis","journal":"Biochemical and biophysical research communications","confidence":"High","confidence_rationale":"Tier 1 — in vitro kinase assay plus in vivo phosphorylation with mutagenesis and functional reporter","pmids":["12435397"],"is_preprint":false},{"year":2003,"finding":"TEL represses the Bcl-XL promoter in a DNA-binding-dependent manner, reducing Bcl-XL mRNA and protein levels, and promotes apoptosis in serum-starved cells; this identifies Bcl-XL as a direct transcriptional target of TEL.","method":"Reporter gene assay, RT-PCR/Western blot for endogenous Bcl-XL, apoptosis assay, domain mutagenesis","journal":"The Journal of biological chemistry","confidence":"Medium","confidence_rationale":"Tier 2 — functional reporter plus endogenous target validation, single study","pmids":["12960174"],"is_preprint":false},{"year":2004,"finding":"TEL-Syk fusion protein (from t(9;12)) is localized in the cytoplasm and constitutively activates PI3K/Akt, Vav, PLCγ2, MAPK, and STAT5 (independently of JAK2); the oligomerization (PNT) domain of TEL is required for all these signaling activities; TEL-Syk confers IL-3-independent growth to Ba/F3 cells.","method":"Immunofluorescence localization, Western blot of signaling pathway activation, Ba/F3 transformation assay, deletion mutagenesis (ΔPNTdomain)","journal":"Leukemia","confidence":"High","confidence_rationale":"Tier 2 — multiple signaling pathways probed with domain mutagenesis and functional transformation assay","pmids":["14749700"],"is_preprint":false},{"year":2004,"finding":"TEL/ETV6 functions as a STAT3-induced repressor of STAT3 activity; STAT3 activates ETV6 transcription, and ETV6 in turn represses STAT3 transcriptional activity through physical recruitment of ETV6 to STAT3 without requiring ETV6 DNA binding, forming a negative feedback loop.","method":"Microarray (STAT3 target identification), siRNA knockdown of TEL, reporter assay, co-immunoprecipitation, ETV6 overexpression","journal":"The Journal of biological chemistry","confidence":"Medium","confidence_rationale":"Tier 2-3 — co-IP plus functional reporter plus siRNA, single study","pmids":["15229229"],"is_preprint":false},{"year":2005,"finding":"The pointed domain of TEL/AML1, which recruits transcriptional repressors and directs oligomerization with TEL/AML1 or wild-type TEL, is essential for impaired B-cell differentiation and increased self-renewal of progenitors in vivo; another oligomerization domain cannot substitute for it.","method":"Bone marrow transplantation model, in vitro replating assays, domain substitution mutagenesis","journal":"Oncogene","confidence":"Medium","confidence_rationale":"Tier 2 — in vivo mouse model with domain replacement, single study","pmids":["16044150"],"is_preprint":false},{"year":2008,"finding":"The F-box protein Fbl6 binds TEL (ETV6) via its SAM (PNT) domain and stimulates ubiquitination of TEL leading to proteasomal degradation; sumoylation of Tel monomers (but not oligomers) sensitizes them for Fbl6-mediated proteasomal degradation, while Tel oligomers are stably sumoylated at K11 but more resistant to degradation.","method":"Co-immunoprecipitation, ubiquitination assay, proteasome inhibitor experiments, sumoylation assay","journal":"Molecular and cellular biology","confidence":"High","confidence_rationale":"Tier 1-2 — biochemical ubiquitination and sumoylation assays with functional protein stability measurements","pmids":["18426905"],"is_preprint":false},{"year":2008,"finding":"TEL (ETV6) is sumoylated at lysine 11 (K11); PIAS3 binds to TEL in the nucleus and stimulates K11 sumoylation; sumoylation of K11 inhibits TEL repression of gene expression by impeding TEL association with DNA; a TelM43 isoform lacking K11 is strongly repressive; PIAS3 can also augment TEL repressive function in a sumoylation-independent manner.","method":"Site-directed mutagenesis of K11, mass spectrometry identification of sumoylation site, co-immunoprecipitation with PIAS3, DNA-binding assay, reporter assay","journal":"Molecular and cellular biology","confidence":"High","confidence_rationale":"Tier 1 — MS-identified sumoylation site, mutagenesis, biochemical DNA-binding and reporter assays","pmids":["18212042"],"is_preprint":false},{"year":2009,"finding":"CBFβ heterodimerization with the Runt domain of AML1 in TEL-AML1 is essential for TEL-AML1's ability to promote self-renewal of B-cell precursors; Runt domain mutations that disrupt CBFβ binding without affecting DNA binding abrogate this function.","method":"Runt domain mutagenesis, B-cell precursor self-renewal assay in vitro, bone marrow reconstitution","journal":"Blood","confidence":"Medium","confidence_rationale":"Tier 2 — domain mutagenesis with functional self-renewal readout, single study","pmids":["19179469"],"is_preprint":false},{"year":2010,"finding":"ETV6-NTRK3-driven transformation of mammary epithelial cells requires the IGF1R/INSR signaling axis; PI3K-Akt is activated in an IGF1- or insulin-dependent manner downstream of ETV6-NTRK3, and dual IGF1R/INSR inhibitors block EN transformation in vitro and tumor growth in vivo.","method":"3D Matrigel culture, tumor formation assay, pharmacological inhibition (BMS-536924, BMS-754807), Western blot of PI3K-Akt signaling","journal":"Cancer research","confidence":"High","confidence_rationale":"Tier 2 — multiple inhibitors, in vitro and in vivo tumor assays, pathway analysis","pmids":["21148487"],"is_preprint":false},{"year":2012,"finding":"ETV6 DNA binding is autoinhibited by two C-terminal helices (H4 and H5) that sterically block the DNA-binding interface of the ETS domain; these helices are only marginally stable and the CID dampens millisecond-timescale motions of the ETS domain critical for specific DNA recognition.","method":"NMR spectroscopy (amide hydrogen exchange, 15N relaxation measurements), structural analysis of ETS domain + CID","journal":"Journal of molecular biology","confidence":"High","confidence_rationale":"Tier 1 — NMR structure with dynamic measurements, mechanistic characterization of autoinhibition","pmids":["22584210"],"is_preprint":false},{"year":2015,"finding":"Germline missense mutations in the ETV6 ETS DNA-binding domain (p.Arg369Gln, p.Arg399Cys) and the internal linker domain (p.Pro214Leu) abrogate DNA binding, alter subcellular localization (cytoplasmic mislocalization of mutant and endogenous ETV6), decrease transcriptional repression in a dominant-negative fashion, and impair megakaryocyte maturation and hematopoiesis.","method":"Whole-exome sequencing, functional reporter assays, subcellular localization by microscopy, megakaryocyte differentiation assay","journal":"Nature genetics","confidence":"High","confidence_rationale":"Tier 2 — multiple functional assays on natural human variants with dominant-negative mechanism characterized","pmids":["25581430"],"is_preprint":false},{"year":2015,"finding":"ETV6 mutations (p.Pro214Leu in central domain; p.Arg418Gly in DNA-binding domain) cause aberrant cytoplasmic localization of both mutant and endogenous ETV6, decreased transcriptional repression, and altered megakaryocyte maturation.","method":"Whole-exome sequencing, subcellular localization microscopy, transcriptional reporter assay, megakaryocyte maturation assay","journal":"Nature genetics","confidence":"High","confidence_rationale":"Tier 2 — multiple orthogonal functional assays with natural human variants","pmids":["25807284"],"is_preprint":false},{"year":2015,"finding":"Germline ETV6 mutations (p.L349P, p.N385fs) impair nuclear localization of ETV6 and significantly reduce its ability to regulate transcription of ETV6 target genes, establishing a dominant-negative mechanism for leukemia predisposition.","method":"Enforced expression of ETV6 mutants, subcellular localization assay, transcriptional target gene reporter assay","journal":"PLoS genetics","confidence":"Medium","confidence_rationale":"Tier 2 — localization and functional assay but single study","pmids":["26102509"],"is_preprint":false},{"year":2016,"finding":"ETV6-RUNX1 fusion drives widespread repression of RUNX1 motif-containing enhancers at target gene loci, including super-enhancers of the CD19+/CD20+ B-cell lineage; this repression depends on the wild-type DNA-binding Runt domain of RUNX1 and results in downregulation of genes involved in B-cell signaling and adhesion.","method":"Global run-on sequencing (GRO-seq), ChIP-seq, enhancer RNA profiling, Runt domain mutant analysis","journal":"Genome research","confidence":"High","confidence_rationale":"Tier 1-2 — genome-wide mechanistic study with domain mutagenesis validation","pmids":["27620872"],"is_preprint":false},{"year":2018,"finding":"ETV6 and ETV3 transcriptional repressors control human monocyte differentiation into dendritic cells by directly repressing MAFB expression (thus suppressing macrophage fate); in vivo, monocyte-specific Etv6 deletion causes spontaneous IFN-stimulated gene expression and impairs mo-DC differentiation during inflammation.","method":"Conditional Etv6 knockout in monocytes, gene expression analysis, MAFB ChIP, DC differentiation assay, EAE model","journal":"Nature immunology","confidence":"High","confidence_rationale":"Tier 2 — conditional KO with defined molecular target (MAFB) and in vivo phenotype","pmids":["36543959"],"is_preprint":false},{"year":2018,"finding":"Etv6 deletion in the bone marrow abolishes CD8α expression on cDC1 conventional dendritic cells in vivo and impairs cDC1-specific gene expression and chromatin signatures while causing aberrant up-regulation of pDC-specific signatures; DC-specific Etv6 deletion impairs CD8+ T-cell cross-priming and tumor-specific T-cell responses.","method":"Bone marrow-specific Etv6 deletion, flow cytometry, gene expression profiling, chromatin accessibility (ATAC-seq-related), cross-priming functional assay","journal":"The Journal of experimental medicine","confidence":"High","confidence_rationale":"Tier 2 — conditional KO with multiple orthogonal functional and epigenomic readouts","pmids":["30087163"],"is_preprint":false},{"year":2019,"finding":"In Xenopus, Etv6 positively regulates vegfa expression during blood stem cell development through two mechanisms: (1) directly repressing the transcriptional repressor foxo3 (preventing Foxo3 from binding and repressing the vegfa promoter — a double-negative gate); (2) directly activating klf4, which then recruits Etv6 to the vegfa promoter to activate its expression (feed-forward loop).","method":"Xenopus embryo loss-of-function (morpholino), ChIP, reporter assay, rescue experiments","journal":"Nature communications","confidence":"Medium","confidence_rationale":"Tier 2 — ChIP and functional epistasis in Xenopus model, mechanistically detailed but single organism","pmids":["30842454"],"is_preprint":false},{"year":2021,"finding":"Germline ETV6 variants linked to ALL predisposition show impaired transcription repressor activity, loss of DNA binding, and altered nuclear localization; missense variants retain dimerization with wild-type ETV6 exerting dominant-negative effects; ATAC-seq profiling identified specific ETV6 genomic targets relevant to tumor suppressor activity.","method":"Functional reporter assay, DNA-binding assay, nuclear localization microscopy, dimerization assay, ATAC-seq, whole-transcriptome and whole-genome sequencing","journal":"Blood","confidence":"High","confidence_rationale":"Tier 1-2 — comprehensive multi-method functional characterization of 22 variants with epigenomic profiling","pmids":["32693409"],"is_preprint":false},{"year":2023,"finding":"ETV6 acts as a transcriptional repressor that competes with EWS-FLI1 for binding to select DNA elements enriched for short GGAA repeat sequences; upon ETV6 inactivation, EWS-FLI1 hyper-activates these cis-elements promoting mesenchymal differentiation (via SOX11); a dominant-interfering ETV6 peptide phenocopies ETV6 loss and suppresses Ewing sarcoma growth in vivo.","method":"CRISPR domain-focused screen, ChIP-seq, ATAC-seq, biochemical competition assay, dominant-interfering peptide, in vivo xenograft","journal":"Nature cell biology","confidence":"High","confidence_rationale":"Tier 1-2 — epigenomics, biochemical competition, and in vivo functional assays in one study","pmids":["36658219"],"is_preprint":false},{"year":2023,"finding":"ETV6 functions as an epigenetic gatekeeper by directly binding GGAA tandem repeat enhancers, repressing their histone acetylation, and downregulating adjacent genes including EPOR; in ETV6-deficient B-ALL, the ETS factor ERG occupies these GGAA microsatellite enhancers and drives aberrant gene activation.","method":"ChIP-seq for ETV6 binding at GGAA repeats, histone acetylation ChIP, ERG knockdown, ETV6 restoration experiments","journal":"Blood cancer discovery","confidence":"High","confidence_rationale":"Tier 1-2 — multiple epigenomic and functional assays defining ETV6's molecular gatekeeper mechanism at GGAA enhancers","pmids":["36350827"],"is_preprint":false}],"current_model":"ETV6 (TEL) is an ETS-family transcriptional repressor that binds GGAA-containing DNA elements through its autoinhibited ETS domain (regulated by C-terminal helices and by PTMs including p38-mediated phosphorylation at Ser22/Ser257 and PIAS3-mediated sumoylation at K11); it recruits corepressor complexes (mSin3A via the pointed/PNT domain, N-CoR and HDAC3 via a central repression domain) to silence target genes including Bcl-XL and EPOR-activating microsatellite enhancers, while its PNT/HLH domain drives homo-oligomerization and, when fused to kinase domains (NTRK3, JAK2, ABL1, etc.) by chromosomal translocations, mediates constitutive kinase activation and oncogenic transformation; in normal hematopoiesis ETV6 is specifically required for bone marrow hematopoietic engraftment, megakaryocyte maturation, and dendritic cell lineage commitment, and germline loss-of-function mutations cause dominant-negative cytoplasmic mislocalization and DNA-binding defects leading to thrombocytopenia and leukemia predisposition."},"narrative":{"teleology":[{"year":1997,"claim":"Establishing TEL as a nuclear phosphoprotein ETS-family DNA-binding factor resolved the basic biochemical identity of the ETV6 gene product, showing it recognizes canonical ETS sites and exists as two phosphorylated isoforms.","evidence":"Western blot, immunofluorescence, and EMSA on murine TEL cDNA products","pmids":["9018121"],"confidence":"High","gaps":["Phosphorylation sites and responsible kinases not identified","Endogenous target genes unknown"]},{"year":1998,"claim":"Discovery that the TEL pointed/HLH domain drives constitutive kinase activation when fused to JAK2 or NTRK3 established the general principle by which ETV6 translocations cause oncogenesis—oligomerization-dependent kinase autophosphorylation.","evidence":"Cloning of t(9;12) TEL-JAK2 and t(12;15) TEL-NTRK3 fusions, in vitro kinase assay, Ba/F3 cytokine-independence assay","pmids":["9360930","9462753"],"confidence":"High","gaps":["Downstream signaling pathways not yet mapped for all fusions","Whether oligomerization suffices or additional PNT-domain functions contribute was unresolved"]},{"year":1998,"claim":"Knockout chimera studies demonstrated that ETV6 is specifically required for bone marrow hematopoiesis—the first transcription factor shown to be dispensable for yolk sac/fetal liver blood formation but essential for marrow engraftment.","evidence":"TEL-/- ES cell chimeras, lineage analysis of hematopoietic organs in mice","pmids":["9694803"],"confidence":"High","gaps":["Direct transcriptional targets mediating engraftment not identified","Whether ETV6 acts cell-autonomously in HSCs vs. niche cells was unresolved"]},{"year":1999,"claim":"Identification of mSin3A, SMRT, and UBC9 as pointed-domain and central-region interactors revealed that ETV6 represses transcription through recruitment of corepressor/HDAC complexes and is post-translationally regulated by the SUMO conjugation machinery.","evidence":"Co-immunoprecipitation, GAL4 reporter assays, deletion mutagenesis, UBC9 interaction assay","pmids":["10490596","10544023","10377438"],"confidence":"High","gaps":["Identity of HDAC isoform in the complex not yet determined","Sumoylation site not mapped"]},{"year":2000,"claim":"Mapping N-CoR recruitment to ETV6's central domain, demonstrating STAT5 as the critical downstream effector of TEL-JAK fusions, and showing TEL overexpression causes G1 arrest and suppresses Ras transformation collectively defined ETV6 as both a tumor suppressor and (when translocated) an oncogene activating JAK-STAT signaling.","evidence":"Co-IP/reporter assays for N-CoR, Ba/F3 assays with dominant-negative STAT5, soft agar and nude mouse assays for tumor suppression","pmids":["11001911","10706877","11077441","10845925"],"confidence":"High","gaps":["Direct target genes mediating G1 arrest not identified","Whether N-CoR and mSin3A act in the same or distinct complexes on chromatin was unclear"]},{"year":2001,"claim":"Demonstration that HDAC3 directly binds ETV6's central region independently of N-CoR, and that HDAC inhibition reverses ETV6-dependent repression and cellular phenotypes, established the chromatin-modifying mechanism underlying ETV6 target gene silencing.","evidence":"Co-IP, ChIP for histone H3 acetylation at stromelysin-1 promoter, trichostatin A treatment","pmids":["11439334"],"confidence":"High","gaps":["Genome-wide target identification not performed","Whether HDAC3 is required at all ETV6-bound loci was unknown"]},{"year":2002,"claim":"Identification of p38 MAPK as a direct ETV6 kinase phosphorylating Ser22 and Ser257 provided the first signal-responsive regulatory mechanism controlling ETV6 repressor activity.","evidence":"In vitro kinase assay, in vivo phosphorylation, site-directed mutagenesis, reporter assay","pmids":["12435397"],"confidence":"High","gaps":["Physiological stimuli triggering p38-ETV6 axis not defined","Functional consequence of each individual phosphosite not fully dissected"]},{"year":2008,"claim":"Mapping sumoylation to K11 by mass spectrometry and showing that PIAS3-catalyzed sumoylation impairs ETV6 DNA binding, while Fbl6-mediated ubiquitination selectively degrades sumoylated monomers, revealed a SUMO–ubiquitin switch governing ETV6 protein stability and activity.","evidence":"Mass spectrometry, sumoylation and ubiquitination assays, proteasome inhibitor experiments, DNA-binding assays","pmids":["18212042","18426905"],"confidence":"High","gaps":["Whether this switch operates in primary hematopoietic cells in vivo is untested","Structural basis of how K11 sumoylation blocks DNA binding not resolved"]},{"year":2012,"claim":"NMR analysis revealed that C-terminal helices H4/H5 autoinhibit the ETS domain by sterically blocking DNA contact and dampening millisecond dynamics required for DNA recognition, explaining how ETV6 DNA binding is kept in check in the absence of activating signals.","evidence":"NMR amide hydrogen exchange and 15N relaxation measurements on ETS domain ± CID","pmids":["22584210"],"confidence":"High","gaps":["What relieves autoinhibition in vivo (partner protein, PTM, or oligomerization) is unknown","No full-length ETV6 structure available"]},{"year":2015,"claim":"Discovery that germline ETV6 mutations cause dominant-negative cytoplasmic mislocalization, impaired DNA binding, and defective megakaryocyte maturation linked ETV6 loss-of-function to inherited thrombocytopenia and leukemia predisposition in humans.","evidence":"Whole-exome sequencing of affected families, functional reporter and localization assays, megakaryocyte differentiation assays","pmids":["25581430","25807284","26102509"],"confidence":"High","gaps":["Mechanism of cytoplasmic mislocalization by linker-domain mutations not structurally explained","Penetrance and modifier genes for leukemia progression unknown"]},{"year":2018,"claim":"Conditional knockout studies established ETV6 as a lineage-determining factor for dendritic cells: it represses MAFB to permit monocyte-to-DC differentiation and maintains cDC1 identity including CD8α expression and cross-priming capacity.","evidence":"Monocyte- and DC-specific Etv6 conditional KO mice, MAFB ChIP, ATAC-seq, cross-priming assays, EAE model","pmids":["36543959","30087163"],"confidence":"High","gaps":["Whether ETV6 cooperates with ETV3 at all DC-specific loci is not resolved","Direct ETV6 chromatin targets in cDC1 not comprehensively mapped"]},{"year":2023,"claim":"Epigenomic studies revealed that ETV6 functions as a gatekeeper at GGAA tandem-repeat microsatellite enhancers, directly binding these elements to maintain repressive histone marks; loss of ETV6 permits replacement by ERG or EWS-FLI1, hyper-activating adjacent genes including EPOR and SOX11.","evidence":"ChIP-seq for ETV6/ERG at GGAA repeats, histone acetylation ChIP, CRISPR screen, dominant-interfering peptide, xenograft assays","pmids":["36658219","36350827"],"confidence":"High","gaps":["Whether ETV6 competes with all ETS factors at GGAA repeats or selectively with ERG/FLI1 is unresolved","Structural basis of ETV6 preference for tandem GGAA repeats not determined"]},{"year":null,"claim":"Key unresolved questions include the full-length structure of ETV6, the mechanism by which autoinhibition is relieved in vivo, the comprehensive identification of direct ETV6 target genes in HSCs mediating bone marrow engraftment, and how ETV6 loss cooperates with secondary hits to drive leukemic transformation.","evidence":"","pmids":[],"confidence":"Low","gaps":["No full-length structural model","In vivo mechanism of autoinhibition relief unknown","Cooperating genetic events for leukemia transformation not systematically defined"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0003677","term_label":"DNA binding","supporting_discovery_ids":[0,7,24,33,34]},{"term_id":"GO:0140110","term_label":"transcription regulator activity","supporting_discovery_ids":[4,5,7,8,12,16,18,25,29,32,34]}],"localization":[{"term_id":"GO:0005634","term_label":"nucleus","supporting_discovery_ids":[0,21,25,26,27]}],"pathway":[{"term_id":"R-HSA-74160","term_label":"Gene expression (Transcription)","supporting_discovery_ids":[4,5,7,8,12,16,29,34]},{"term_id":"R-HSA-4839726","term_label":"Chromatin organization","supporting_discovery_ids":[12,34]},{"term_id":"R-HSA-1266738","term_label":"Developmental Biology","supporting_discovery_ids":[3,25,29,30]},{"term_id":"R-HSA-168256","term_label":"Immune System","supporting_discovery_ids":[29,30]},{"term_id":"R-HSA-1643685","term_label":"Disease","supporting_discovery_ids":[1,2,13,14,25,32,33]}],"complexes":["N-CoR/HDAC3 corepressor complex","mSin3A corepressor complex"],"partners":["NCOR1","HDAC3","SIN3A","PIAS3","UBE2I","FBXL6","MAPK14","STAT3"],"other_free_text":[]},"mechanistic_narrative":"ETV6 (TEL) is an ETS-family transcriptional repressor that governs hematopoietic stem cell engraftment, megakaryocyte maturation, and dendritic cell lineage commitment, and whose disruption by chromosomal translocation or germline mutation drives leukemia and solid tumor pathogenesis. ETV6 binds GGAA-containing DNA elements through an autoinhibited ETS domain regulated by marginally stable C-terminal helices [PMID:22584210], and represses target genes—including Bcl-XL, MAFB, and GGAA-microsatellite enhancers controlling EPOR—by recruiting mSin3A via its pointed/PNT domain and N-CoR/HDAC3 via a central repression domain [PMID:10490596, PMID:11439334, PMID:36350827]. Its activity is modulated by p38-mediated phosphorylation at Ser22/Ser257, PIAS3-mediated sumoylation at K11 (which impairs DNA binding), and Fbl6-directed ubiquitin-proteasomal degradation of sumoylated monomers [PMID:12435397, PMID:18212042, PMID:18426905]. Germline loss-of-function mutations in ETV6 cause dominant-negative cytoplasmic mislocalization and defective transcriptional repression, resulting in thrombocytopenia and predisposition to acute lymphoblastic leukemia, while the PNT domain's oligomerization capacity is co-opted by chromosomal translocations that constitutively activate partner kinases such as JAK2, NTRK3, and ABL1 [PMID:25581430, PMID:9360930, PMID:9462753]."},"prefetch_data":{"uniprot":{"accession":"P41212","full_name":"Transcription factor ETV6","aliases":["ETS translocation variant 6","ETS-related protein Tel1","Tel"],"length_aa":452,"mass_kda":53.0,"function":"Transcriptional repressor; binds to the DNA sequence 5'-CCGGAAGT-3'. Plays a role in hematopoiesis and malignant transformation","subcellular_location":"Nucleus","url":"https://www.uniprot.org/uniprotkb/P41212/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/ETV6","classification":"Not Classified","n_dependent_lines":24,"n_total_lines":1208,"dependency_fraction":0.019867549668874173},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[{"gene":"VPS35","stoichiometry":0.2}],"url":"https://opencell.sf.czbiohub.org/search/ETV6","total_profiled":1310},"omim":[{"mim_id":"618592","title":"RING FINGER PROTEIN 217; RNF217","url":"https://www.omim.org/entry/618592"},{"mim_id":"616216","title":"THROMBOCYTOPENIA 5; THC5","url":"https://www.omim.org/entry/616216"},{"mim_id":"615958","title":"SLX4-INTERACTING PROTEIN; SLX4IP","url":"https://www.omim.org/entry/615958"},{"mim_id":"615545","title":"LEUKEMIA, ACUTE LYMPHOBLASTIC, SUSCEPTIBILITY TO, 3; ALL3","url":"https://www.omim.org/entry/615545"},{"mim_id":"613065","title":"LEUKEMIA, ACUTE LYMPHOBLASTIC; ALL","url":"https://www.omim.org/entry/613065"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Approved","locations":[{"location":"Nucleoli","reliability":"Approved"},{"location":"Cytosol","reliability":"Additional"}],"tissue_specificity":"Low tissue specificity","tissue_distribution":"Detected in all","driving_tissues":[],"url":"https://www.proteinatlas.org/search/ETV6"},"hgnc":{"alias_symbol":["TEL"],"prev_symbol":[]},"alphafold":{"accession":"P41212","domains":[{"cath_id":"1.10.150.50","chopping":"51-123","consensus_level":"high","plddt":87.1038,"start":51,"end":123},{"cath_id":"1.10.10.10","chopping":"340-444","consensus_level":"high","plddt":88.2818,"start":340,"end":444}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/P41212","model_url":"https://alphafold.ebi.ac.uk/files/AF-P41212-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-P41212-F1-predicted_aligned_error_v6.png","plddt_mean":61.81},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=ETV6","jax_strain_url":"https://www.jax.org/strain/search?query=ETV6"},"sequence":{"accession":"P41212","fasta_url":"https://rest.uniprot.org/uniprotkb/P41212.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/P41212/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/P41212"}},"corpus_meta":[{"pmid":"12450792","id":"PMC_12450792","title":"Expression of the ETV6-NTRK3 gene fusion as a primary event in human secretory breast carcinoma.","date":"2002","source":"Cancer cell","url":"https://pubmed.ncbi.nlm.nih.gov/12450792","citation_count":689,"is_preprint":false},{"pmid":"9360930","id":"PMC_9360930","title":"A TEL-JAK2 fusion protein with constitutive kinase activity in human leukemia.","date":"1997","source":"Science (New York, N.Y.)","url":"https://pubmed.ncbi.nlm.nih.gov/9360930","citation_count":661,"is_preprint":false},{"pmid":"9462753","id":"PMC_9462753","title":"A novel ETV6-NTRK3 gene fusion in congenital fibrosarcoma.","date":"1998","source":"Nature genetics","url":"https://pubmed.ncbi.nlm.nih.gov/9462753","citation_count":628,"is_preprint":false},{"pmid":"18202291","id":"PMC_18202291","title":"Initiating and cancer-propagating cells in TEL-AML1-associated childhood leukemia.","date":"2008","source":"Science (New York, N.Y.)","url":"https://pubmed.ncbi.nlm.nih.gov/18202291","citation_count":295,"is_preprint":false},{"pmid":"25581430","id":"PMC_25581430","title":"Germline ETV6 mutations in familial thrombocytopenia and hematologic malignancy.","date":"2015","source":"Nature genetics","url":"https://pubmed.ncbi.nlm.nih.gov/25581430","citation_count":279,"is_preprint":false},{"pmid":"23103865","id":"PMC_23103865","title":"The TEL patch of telomere protein TPP1 mediates telomerase recruitment and processivity.","date":"2012","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/23103865","citation_count":278,"is_preprint":false},{"pmid":"8943861","id":"PMC_8943861","title":"TEL/AML-1 dimerizes and is associated with a favorable outcome in childhood acute lymphoblastic leukemia.","date":"1996","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/8943861","citation_count":263,"is_preprint":false},{"pmid":"28098529","id":"PMC_28098529","title":"Multidrug-Resistant Candida haemulonii and C. auris, Tel Aviv, Israel.","date":"2017","source":"Emerging infectious diseases","url":"https://pubmed.ncbi.nlm.nih.gov/28098529","citation_count":254,"is_preprint":false},{"pmid":"10895816","id":"PMC_10895816","title":"Molecular detection of the ETV6-NTRK3 gene fusion differentiates congenital fibrosarcoma from other childhood spindle cell tumors.","date":"2000","source":"The American journal of surgical pathology","url":"https://pubmed.ncbi.nlm.nih.gov/10895816","citation_count":253,"is_preprint":false},{"pmid":"25807284","id":"PMC_25807284","title":"Germline mutations in ETV6 are associated with thrombocytopenia, red cell macrocytosis and predisposition to lymphoblastic leukemia.","date":"2015","source":"Nature genetics","url":"https://pubmed.ncbi.nlm.nih.gov/25807284","citation_count":221,"is_preprint":false},{"pmid":"9694803","id":"PMC_9694803","title":"The TEL/ETV6 gene is required specifically for hematopoiesis in the bone marrow.","date":"1998","source":"Genes & development","url":"https://pubmed.ncbi.nlm.nih.gov/9694803","citation_count":220,"is_preprint":false},{"pmid":"22162831","id":"PMC_22162831","title":"ETV6 mutations in early immature human T cell leukemias.","date":"2011","source":"The Journal of experimental medicine","url":"https://pubmed.ncbi.nlm.nih.gov/22162831","citation_count":170,"is_preprint":false},{"pmid":"26606880","id":"PMC_26606880","title":"Transcriptome sequencing identifies ETV6-NTRK3 as a gene fusion involved in GIST.","date":"2016","source":"The Journal of pathology","url":"https://pubmed.ncbi.nlm.nih.gov/26606880","citation_count":156,"is_preprint":false},{"pmid":"10490596","id":"PMC_10490596","title":"Both TEL and AML-1 contribute repression domains to the t(12;21) fusion protein.","date":"1999","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/10490596","citation_count":132,"is_preprint":false},{"pmid":"10544023","id":"PMC_10544023","title":"The leukemia-associated gene TEL encodes a transcription repressor which associates with SMRT and mSin3A.","date":"1999","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/10544023","citation_count":124,"is_preprint":false},{"pmid":"26102509","id":"PMC_26102509","title":"Germline ETV6 Mutations Confer Susceptibility to Acute Lymphoblastic Leukemia and Thrombocytopenia.","date":"2015","source":"PLoS genetics","url":"https://pubmed.ncbi.nlm.nih.gov/26102509","citation_count":118,"is_preprint":false},{"pmid":"10706877","id":"PMC_10706877","title":"Transforming properties of chimeric TEL-JAK proteins in Ba/F3 cells.","date":"2000","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/10706877","citation_count":117,"is_preprint":false},{"pmid":"10845925","id":"PMC_10845925","title":"TEL-JAK2 transgenic mice develop T-cell leukemia.","date":"2000","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/10845925","citation_count":103,"is_preprint":false},{"pmid":"9018121","id":"PMC_9018121","title":"The TEL gene products: nuclear phosphoproteins with DNA binding properties.","date":"1997","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/9018121","citation_count":99,"is_preprint":false},{"pmid":"11001911","id":"PMC_11001911","title":"Recruitment of the nuclear receptor corepressor N-CoR by the TEL moiety of the childhood leukemia-associated TEL-AML1 oncoprotein.","date":"2000","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/11001911","citation_count":99,"is_preprint":false},{"pmid":"28637624","id":"PMC_28637624","title":"ETV6 in hematopoiesis and leukemia predisposition.","date":"2017","source":"Seminars in hematology","url":"https://pubmed.ncbi.nlm.nih.gov/28637624","citation_count":97,"is_preprint":false},{"pmid":"10049061","id":"PMC_10049061","title":"The role of TEL fusion genes in pediatric leukemias.","date":"1999","source":"Leukemia","url":"https://pubmed.ncbi.nlm.nih.gov/10049061","citation_count":96,"is_preprint":false},{"pmid":"19890372","id":"PMC_19890372","title":"Hsa-mir-125b-2 is highly expressed in childhood ETV6/RUNX1 (TEL/AML1) leukemias and confers survival advantage to growth inhibitory signals independent of p53.","date":"2009","source":"Leukemia","url":"https://pubmed.ncbi.nlm.nih.gov/19890372","citation_count":94,"is_preprint":false},{"pmid":"11439334","id":"PMC_11439334","title":"TEL contacts multiple co-repressors and specifically associates with histone deacetylase-3.","date":"2001","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/11439334","citation_count":88,"is_preprint":false},{"pmid":"30130630","id":"PMC_30130630","title":"Novel gene fusions in secretory carcinoma of the salivary glands: enlarging the ETV6 family.","date":"2018","source":"Human pathology","url":"https://pubmed.ncbi.nlm.nih.gov/30130630","citation_count":85,"is_preprint":false},{"pmid":"21401966","id":"PMC_21401966","title":"Characterization of a newly identified ETV6-NTRK3 fusion transcript in acute myeloid leukemia.","date":"2011","source":"Diagnostic pathology","url":"https://pubmed.ncbi.nlm.nih.gov/21401966","citation_count":78,"is_preprint":false},{"pmid":"27229714","id":"PMC_27229714","title":"Characterization of leukemias with ETV6-ABL1 fusion.","date":"2016","source":"Haematologica","url":"https://pubmed.ncbi.nlm.nih.gov/27229714","citation_count":77,"is_preprint":false},{"pmid":"10377438","id":"PMC_10377438","title":"Modulation of TEL transcription activity by interaction with the ubiquitin-conjugating enzyme UBC9.","date":"1999","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/10377438","citation_count":75,"is_preprint":false},{"pmid":"16044150","id":"PMC_16044150","title":"Defining the oncogenic function of the TEL/AML1 (ETV6/RUNX1) fusion protein in a mouse model.","date":"2005","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/16044150","citation_count":74,"is_preprint":false},{"pmid":"28630052","id":"PMC_28630052","title":"Infection Exposure Promotes ETV6-RUNX1 Precursor B-cell Leukemia via Impaired H3K4 Demethylases.","date":"2017","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/28630052","citation_count":73,"is_preprint":false},{"pmid":"10463610","id":"PMC_10463610","title":"Structure and possible mechanisms of TEL-AML1 gene fusions in childhood acute lymphoblastic leukemia.","date":"1999","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/10463610","citation_count":69,"is_preprint":false},{"pmid":"20807887","id":"PMC_20807887","title":"TEL-AML1 regulation of survivin and apoptosis via miRNA-494 and miRNA-320a.","date":"2010","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/20807887","citation_count":64,"is_preprint":false},{"pmid":"31248877","id":"PMC_31248877","title":"ETV6-related thrombocytopenia and leukemia predisposition.","date":"2019","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/31248877","citation_count":62,"is_preprint":false},{"pmid":"9050885","id":"PMC_9050885","title":"Functional characterization of ETV6 and ETV6/CBFA2 in the regulation of the MCSFR proximal promoter.","date":"1997","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/9050885","citation_count":61,"is_preprint":false},{"pmid":"32693409","id":"PMC_32693409","title":"Molecular basis of ETV6-mediated predisposition to childhood acute lymphoblastic leukemia.","date":"2021","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/32693409","citation_count":57,"is_preprint":false},{"pmid":"28418909","id":"PMC_28418909","title":"Pathogenesis of ETV6/RUNX1-positive childhood acute lymphoblastic leukemia and mechanisms underlying its relapse.","date":"2017","source":"Oncotarget","url":"https://pubmed.ncbi.nlm.nih.gov/28418909","citation_count":56,"is_preprint":false},{"pmid":"16681692","id":"PMC_16681692","title":"Expression of ETV6-NTRK in classical, cellular and mixed subtypes of congenital mesoblastic nephroma.","date":"2006","source":"Histopathology","url":"https://pubmed.ncbi.nlm.nih.gov/16681692","citation_count":50,"is_preprint":false},{"pmid":"11066076","id":"PMC_11066076","title":"t(7;12)(q36;p13), a new recurrent translocation involving ETV6 in infant leukemia.","date":"2000","source":"Genes, chromosomes & cancer","url":"https://pubmed.ncbi.nlm.nih.gov/11066076","citation_count":49,"is_preprint":false},{"pmid":"27020209","id":"PMC_27020209","title":"Congenital mesoblastic nephroma: a study of 19 cases using immunohistochemistry and ETV6-NTRK3 fusion gene rearrangement.","date":"2015","source":"Pathology","url":"https://pubmed.ncbi.nlm.nih.gov/27020209","citation_count":49,"is_preprint":false},{"pmid":"25388957","id":"PMC_25388957","title":"Clonal origins of ETV6-RUNX1⁺ acute lymphoblastic leukemia: studies in monozygotic twins.","date":"2014","source":"Leukemia","url":"https://pubmed.ncbi.nlm.nih.gov/25388957","citation_count":48,"is_preprint":false},{"pmid":"21148487","id":"PMC_21148487","title":"ETV6-NTRK3-mediated breast epithelial cell transformation is blocked by targeting the IGF1R signaling pathway.","date":"2010","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/21148487","citation_count":48,"is_preprint":false},{"pmid":"29046324","id":"PMC_29046324","title":"ETV6-NTRK3 and STRN-ALK kinase fusions are recurrent events in papillary thyroid cancer of adult population.","date":"2017","source":"European journal of endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/29046324","citation_count":46,"is_preprint":false},{"pmid":"36543959","id":"PMC_36543959","title":"ETV3 and ETV6 enable monocyte differentiation into dendritic cells by repressing macrophage fate commitment.","date":"2022","source":"Nature immunology","url":"https://pubmed.ncbi.nlm.nih.gov/36543959","citation_count":45,"is_preprint":false},{"pmid":"19179469","id":"PMC_19179469","title":"CBFbeta is critical for AML1-ETO and TEL-AML1 activity.","date":"2009","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/19179469","citation_count":45,"is_preprint":false},{"pmid":"11108721","id":"PMC_11108721","title":"Tel-2 is a novel transcriptional repressor related to the Ets factor Tel/ETV-6.","date":"2000","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/11108721","citation_count":45,"is_preprint":false},{"pmid":"22094587","id":"PMC_22094587","title":"Silencing of ETV6/RUNX1 abrogates PI3K/AKT/mTOR signaling and impairs reconstitution of leukemia in xenografts.","date":"2011","source":"Leukemia","url":"https://pubmed.ncbi.nlm.nih.gov/22094587","citation_count":43,"is_preprint":false},{"pmid":"19644140","id":"PMC_19644140","title":"The fusion proteins TEL-PDGFRbeta and FIP1L1-PDGFRalpha escape ubiquitination and degradation.","date":"2009","source":"Haematologica","url":"https://pubmed.ncbi.nlm.nih.gov/19644140","citation_count":42,"is_preprint":false},{"pmid":"14749700","id":"PMC_14749700","title":"TEL-Syk fusion constitutively activates PI3-K/Akt, MAPK and JAK2-independent STAT5 signal pathways.","date":"2004","source":"Leukemia","url":"https://pubmed.ncbi.nlm.nih.gov/14749700","citation_count":42,"is_preprint":false},{"pmid":"11077441","id":"PMC_11077441","title":"Tel induces a G1 arrest and suppresses Ras-induced transformation.","date":"2000","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/11077441","citation_count":42,"is_preprint":false},{"pmid":"36658219","id":"PMC_36658219","title":"ETV6 dependency in Ewing sarcoma by antagonism of EWS-FLI1-mediated enhancer activation.","date":"2023","source":"Nature cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/36658219","citation_count":40,"is_preprint":false},{"pmid":"24339741","id":"PMC_24339741","title":"ETV6/RUNX1 induces reactive oxygen species and drives the accumulation of DNA damage in B cells.","date":"2013","source":"Neoplasia (New York, N.Y.)","url":"https://pubmed.ncbi.nlm.nih.gov/24339741","citation_count":40,"is_preprint":false},{"pmid":"28219927","id":"PMC_28219927","title":"Molecular role of the PAX5-ETV6 oncoprotein in promoting B-cell acute lymphoblastic leukemia.","date":"2017","source":"The EMBO journal","url":"https://pubmed.ncbi.nlm.nih.gov/28219927","citation_count":40,"is_preprint":false},{"pmid":"12036890","id":"PMC_12036890","title":"The Tel-Abl (ETV6-Abl) tyrosine kinase, product of complex (9;12) translocations in human leukemia, induces distinct myeloproliferative disease in mice.","date":"2002","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/12036890","citation_count":39,"is_preprint":false},{"pmid":"9864173","id":"PMC_9864173","title":"ETV6-AML1 translocation breakpoints cluster near a purine/pyrimidine repeat region in the ETV6 gene.","date":"1999","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/9864173","citation_count":39,"is_preprint":false},{"pmid":"30087163","id":"PMC_30087163","title":"Transcription factor Etv6 regulates functional differentiation of cross-presenting classical dendritic cells.","date":"2018","source":"The Journal of experimental medicine","url":"https://pubmed.ncbi.nlm.nih.gov/30087163","citation_count":38,"is_preprint":false},{"pmid":"9171997","id":"PMC_9171997","title":"Deletions of CDKN1B and ETV6 in acute myeloid leukemia and myelodysplastic syndromes without cytogenetic evidence of 12p abnormalities.","date":"1997","source":"Genes, chromosomes & cancer","url":"https://pubmed.ncbi.nlm.nih.gov/9171997","citation_count":37,"is_preprint":false},{"pmid":"18426905","id":"PMC_18426905","title":"Downregulation of vertebrate Tel (ETV6) and Drosophila Yan is facilitated by an evolutionarily conserved mechanism of F-box-mediated ubiquitination.","date":"2008","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/18426905","citation_count":35,"is_preprint":false},{"pmid":"22373549","id":"PMC_22373549","title":"Detection of ETV6 gene rearrangements in adult acute lymphoblastic leukemia.","date":"2012","source":"Annals of hematology","url":"https://pubmed.ncbi.nlm.nih.gov/22373549","citation_count":35,"is_preprint":false},{"pmid":"22028862","id":"PMC_22028862","title":"The leukemia-specific fusion gene ETV6/RUNX1 perturbs distinct key biological functions primarily by gene repression.","date":"2011","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/22028862","citation_count":35,"is_preprint":false},{"pmid":"16105979","id":"PMC_16105979","title":"Conditional MN1-TEL knock-in mice develop acute myeloid leukemia in conjunction with overexpression of HOXA9.","date":"2005","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/16105979","citation_count":35,"is_preprint":false},{"pmid":"9671410","id":"PMC_9671410","title":"Analysis of TEL proteins in human leukemias.","date":"1998","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/9671410","citation_count":34,"is_preprint":false},{"pmid":"30088951","id":"PMC_30088951","title":"FOXO1 and ETV6 genes may represent novel regulators of splicing factor expression in cellular senescence.","date":"2018","source":"FASEB journal : official publication of the Federation of American Societies for Experimental Biology","url":"https://pubmed.ncbi.nlm.nih.gov/30088951","citation_count":33,"is_preprint":false},{"pmid":"29237803","id":"PMC_29237803","title":"Antitumor Activity of Entrectinib, a Pan-TRK, ROS1, and ALK Inhibitor, in ETV6-NTRK3-Positive Acute Myeloid Leukemia.","date":"2017","source":"Molecular cancer therapeutics","url":"https://pubmed.ncbi.nlm.nih.gov/29237803","citation_count":32,"is_preprint":false},{"pmid":"11314018","id":"PMC_11314018","title":"The TEL-Jak2 oncoprotein induces Socs1 expression and altered cytokine response in Ba/F3 cells.","date":"2001","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/11314018","citation_count":31,"is_preprint":false},{"pmid":"15325275","id":"PMC_15325275","title":"TEL/AML1 shows dominant-negative effects over TEL as well as AML1.","date":"2004","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/15325275","citation_count":31,"is_preprint":false},{"pmid":"22584210","id":"PMC_22584210","title":"Autoinhibition of ETV6 (TEL) DNA binding: appended helices sterically block the ETS domain.","date":"2012","source":"Journal of molecular biology","url":"https://pubmed.ncbi.nlm.nih.gov/22584210","citation_count":30,"is_preprint":false},{"pmid":"27620872","id":"PMC_27620872","title":"Genome-wide repression of eRNA and target gene loci by the ETV6-RUNX1 fusion in acute leukemia.","date":"2016","source":"Genome research","url":"https://pubmed.ncbi.nlm.nih.gov/27620872","citation_count":30,"is_preprint":false},{"pmid":"19010836","id":"PMC_19010836","title":"Role of the erythropoietin receptor in ETV6/RUNX1-positive acute lymphoblastic leukemia.","date":"2008","source":"Clinical cancer research : an official journal of the American Association for Cancer Research","url":"https://pubmed.ncbi.nlm.nih.gov/19010836","citation_count":30,"is_preprint":false},{"pmid":"12960174","id":"PMC_12960174","title":"TEL, a putative tumor suppressor, induces apoptosis and represses transcription of Bcl-XL.","date":"2003","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/12960174","citation_count":29,"is_preprint":false},{"pmid":"28650474","id":"PMC_28650474","title":"An activating mutation of GNB1 is associated with resistance to tyrosine kinase inhibitors in ETV6-ABL1-positive leukemia.","date":"2017","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/28650474","citation_count":28,"is_preprint":false},{"pmid":"18212042","id":"PMC_18212042","title":"Identification of a new site of sumoylation on Tel (ETV6) uncovers a PIAS-dependent mode of regulating Tel function.","date":"2008","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/18212042","citation_count":28,"is_preprint":false},{"pmid":"25213837","id":"PMC_25213837","title":"Haploinsufficiency of ETV6 and CDKN1B in patients with acute myeloid leukemia and complex karyotype.","date":"2014","source":"BMC genomics","url":"https://pubmed.ncbi.nlm.nih.gov/25213837","citation_count":27,"is_preprint":false},{"pmid":"17095626","id":"PMC_17095626","title":"RNAi-mediated silencing of TEL/AML1 reveals a heat-shock protein- and survivin-dependent mechanism for survival.","date":"2006","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/17095626","citation_count":27,"is_preprint":false},{"pmid":"17077140","id":"PMC_17077140","title":"Expression of TEL-JAK2 in primary human hematopoietic cells drives erythropoietin-independent erythropoiesis and induces myelofibrosis in vivo.","date":"2006","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/17077140","citation_count":27,"is_preprint":false},{"pmid":"15229229","id":"PMC_15229229","title":"TEL/ETV6 is a signal transducer and activator of transcription 3 (Stat3)-induced repressor of Stat3 activity.","date":"2004","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/15229229","citation_count":26,"is_preprint":false},{"pmid":"34336858","id":"PMC_34336858","title":"The Second Oncogenic Hit Determines the Cell Fate of ETV6-RUNX1 Positive Leukemia.","date":"2021","source":"Frontiers in cell and developmental biology","url":"https://pubmed.ncbi.nlm.nih.gov/34336858","citation_count":26,"is_preprint":false},{"pmid":"12435397","id":"PMC_12435397","title":"Functional regulation of TEL by p38-induced phosphorylation.","date":"2002","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/12435397","citation_count":25,"is_preprint":false},{"pmid":"22865910","id":"PMC_22865910","title":"Gene duplication within the Green Lineage: the case of TEL genes.","date":"2012","source":"Journal of experimental botany","url":"https://pubmed.ncbi.nlm.nih.gov/22865910","citation_count":24,"is_preprint":false},{"pmid":"26269126","id":"PMC_26269126","title":"Somatic drivers of B-ALL in a model of ETV6-RUNX1; Pax5(+/-) leukemia.","date":"2015","source":"BMC cancer","url":"https://pubmed.ncbi.nlm.nih.gov/26269126","citation_count":24,"is_preprint":false},{"pmid":"27540136","id":"PMC_27540136","title":"CLIC5: a novel ETV6 target gene in childhood acute lymphoblastic leukemia.","date":"2016","source":"Haematologica","url":"https://pubmed.ncbi.nlm.nih.gov/27540136","citation_count":23,"is_preprint":false},{"pmid":"30940639","id":"PMC_30940639","title":"Germline deletion of ETV6 in familial acute lymphoblastic leukemia.","date":"2019","source":"Blood advances","url":"https://pubmed.ncbi.nlm.nih.gov/30940639","citation_count":23,"is_preprint":false},{"pmid":"11343784","id":"PMC_11343784","title":"Low incidence of TEL/AML1 fusion and TEL deletion in Korean childhood acute leukemia by extra-signal fluorescence in situ hybridization.","date":"2001","source":"Cancer genetics and cytogenetics","url":"https://pubmed.ncbi.nlm.nih.gov/11343784","citation_count":23,"is_preprint":false},{"pmid":"29894279","id":"PMC_29894279","title":"Acute myeloid leukemia carrying ETV6 mutations: biologic and clinical features.","date":"2018","source":"Hematology (Amsterdam, Netherlands)","url":"https://pubmed.ncbi.nlm.nih.gov/29894279","citation_count":21,"is_preprint":false},{"pmid":"27604872","id":"PMC_27604872","title":"A quantitative proteomics approach identifies ETV6 and IKZF1 as new regulators of an ERG-driven transcriptional network.","date":"2016","source":"Nucleic acids research","url":"https://pubmed.ncbi.nlm.nih.gov/27604872","citation_count":21,"is_preprint":false},{"pmid":"28299659","id":"PMC_28299659","title":"Mechanism of ETV6-RUNX1 Leukemia.","date":"2017","source":"Advances in experimental medicine and biology","url":"https://pubmed.ncbi.nlm.nih.gov/28299659","citation_count":20,"is_preprint":false},{"pmid":"36350827","id":"PMC_36350827","title":"ETV6 Deficiency Unlocks ERG-Dependent Microsatellite Enhancers to Drive Aberrant Gene Activation in B-Lymphoblastic Leukemia.","date":"2023","source":"Blood cancer discovery","url":"https://pubmed.ncbi.nlm.nih.gov/36350827","citation_count":19,"is_preprint":false},{"pmid":"29034503","id":"PMC_29034503","title":"Detection of a new heterozygous germline ETV6 mutation in a case with hyperdiploid acute lymphoblastic leukemia.","date":"2017","source":"European journal of haematology","url":"https://pubmed.ncbi.nlm.nih.gov/29034503","citation_count":19,"is_preprint":false},{"pmid":"31429529","id":"PMC_31429529","title":"The study of METTL3 and METTL14 expressions in childhood ETV6/RUNX1-positive acute lymphoblastic leukemia.","date":"2019","source":"Molecular genetics & genomic medicine","url":"https://pubmed.ncbi.nlm.nih.gov/31429529","citation_count":19,"is_preprint":false},{"pmid":"25298122","id":"PMC_25298122","title":"Identification and characterization of OSTL (RNF217) encoding a RING-IBR-RING protein adjacent to a translocation breakpoint involving ETV6 in childhood ALL.","date":"2014","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/25298122","citation_count":19,"is_preprint":false},{"pmid":"32659251","id":"PMC_32659251","title":"ETV6 gene aberrations in non-haematological malignancies: A review highlighting ETV6 associated fusion genes in solid tumors.","date":"2020","source":"Biochimica et biophysica acta. Reviews on cancer","url":"https://pubmed.ncbi.nlm.nih.gov/32659251","citation_count":18,"is_preprint":false},{"pmid":"12080468","id":"PMC_12080468","title":"Transformation of Ba/F3 cells and Rat-1 cells by ETV6/ARG.","date":"2002","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/12080468","citation_count":18,"is_preprint":false},{"pmid":"23171811","id":"PMC_23171811","title":"Variant of ETV6/ABL1 gene is associated with leukemia phenotype.","date":"2012","source":"Acta haematologica","url":"https://pubmed.ncbi.nlm.nih.gov/23171811","citation_count":17,"is_preprint":false},{"pmid":"32326970","id":"PMC_32326970","title":"A novel ETV6-miR-429-CRKL regulatory circuitry contributes to aggressiveness of hepatocellular carcinoma.","date":"2020","source":"Journal of experimental & clinical cancer research : CR","url":"https://pubmed.ncbi.nlm.nih.gov/32326970","citation_count":17,"is_preprint":false},{"pmid":"26711002","id":"PMC_26711002","title":"Determination of ETV6-RUNX1 genomic breakpoint by next-generation sequencing.","date":"2015","source":"Cancer medicine","url":"https://pubmed.ncbi.nlm.nih.gov/26711002","citation_count":17,"is_preprint":false},{"pmid":"10935500","id":"PMC_10935500","title":"Tel, a frequent target of leukemic translocations, induces cellular aggregation and influences expression of extracellular matrix components.","date":"1999","source":"Neoplasia (New York, N.Y.)","url":"https://pubmed.ncbi.nlm.nih.gov/10935500","citation_count":17,"is_preprint":false},{"pmid":"30842454","id":"PMC_30842454","title":"Etv6 activates vegfa expression through positive and negative transcriptional regulatory networks in Xenopus embryos.","date":"2019","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/30842454","citation_count":16,"is_preprint":false},{"pmid":"17069581","id":"PMC_17069581","title":"Identification of transcripts modulated by ETV6 expression.","date":"2006","source":"British journal of haematology","url":"https://pubmed.ncbi.nlm.nih.gov/17069581","citation_count":16,"is_preprint":false},{"pmid":"12210491","id":"PMC_12210491","title":"Mutational analysis of ETV6 in prostate carcinoma.","date":"2002","source":"The Prostate","url":"https://pubmed.ncbi.nlm.nih.gov/12210491","citation_count":16,"is_preprint":false},{"pmid":"29119387","id":"PMC_29119387","title":"A new ETV6-NTRK3 cell line model reveals MALAT1 as a novel therapeutic target - a short report.","date":"2017","source":"Cellular oncology (Dordrecht, Netherlands)","url":"https://pubmed.ncbi.nlm.nih.gov/29119387","citation_count":16,"is_preprint":false},{"pmid":"31181727","id":"PMC_31181727","title":"ZBTB46, SPDEF, and ETV6: Novel Potential Biomarkers and Therapeutic Targets in Castration-Resistant Prostate Cancer.","date":"2019","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/31181727","citation_count":15,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":47855,"output_tokens":7933,"usd":0.13128},"stage2":{"model":"claude-opus-4-6","input_tokens":11713,"output_tokens":3446,"usd":0.217073},"total_usd":0.348353,"stage1_batch_id":"msgbatch_0118RScg3WGaGkaZRtWZbtce","stage2_batch_id":"msgbatch_01Cpfzvtbj42aqp5oYZ5Te2s","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 1997,\n      \"finding\": \"TEL (ETV6) protein products are nuclear phosphoproteins that display specific DNA-binding activity toward classical ETS binding sites; two isoforms of 50 kDa and 57 kDa are produced by translation initiation at either of the two first in-frame ATGs (codon 1 and 43), and both are modified by multiple phosphorylation events in vivo.\",\n      \"method\": \"Western blot, immunofluorescence, EMSA, murine TEL cDNA isolation\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — direct biochemical characterization with multiple orthogonal methods (Western, immunofluorescence, EMSA)\",\n      \"pmids\": [\"9018121\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1997,\n      \"finding\": \"The TEL-JAK2 fusion protein, generated by t(9;12)(p24;p13), includes the TEL oligomerization (pointed/HLH) domain fused to the JAK2 catalytic domain; TEL-induced oligomerization results in constitutive tyrosine kinase activity and confers cytokine-independent proliferation to Ba/F3 cells.\",\n      \"method\": \"Characterization of t(9;12) translocation product, in vitro kinase assay, Ba/F3 growth factor independence assay\",\n      \"journal\": \"Science\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — original discovery with biochemical kinase activation assay and functional cell transformation, replicated in subsequent work\",\n      \"pmids\": [\"9360930\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1998,\n      \"finding\": \"The ETV6-NTRK3 fusion gene, arising from t(12;15)(p13;q25) in congenital fibrosarcoma, encodes a chimeric protein containing the ETV6 helix-loop-helix (HLH) dimerization domain fused to the NTRK3 protein tyrosine kinase domain, producing a constitutively active chimeric tyrosine kinase.\",\n      \"method\": \"Cloning of chromosomal breakpoints, RT-PCR, sequencing of fusion transcripts\",\n      \"journal\": \"Nature genetics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — original cloning and molecular characterization of fusion gene structure, widely replicated\",\n      \"pmids\": [\"9462753\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1998,\n      \"finding\": \"TEL (ETV6) is required specifically for hematopoiesis in the bone marrow; TEL-/- hematopoietic cells can populate yolk sac and fetal liver but fail to establish bone marrow hematopoiesis, establishing TEL as the first transcription factor specifically required for bone marrow hematopoietic activity.\",\n      \"method\": \"Gene targeting in mice, chimera generation with TEL-/- ES cells, lineage analysis\",\n      \"journal\": \"Genes & development\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — clean knockout with defined cellular phenotype, rigorous in vivo model\",\n      \"pmids\": [\"9694803\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1999,\n      \"finding\": \"The TEL pointed (HLH) domain functions as a portable transcriptional repression motif; the TEL-AML1 fusion protein and wild-type TEL both bind the mSin3A corepressor via the pointed domain, and AML1B also contributes an mSin3-interaction domain to the fusion protein, making the complex bind mSin3A more stably than either alone.\",\n      \"method\": \"GAL4 reporter assays, deletion mutagenesis, co-immunoprecipitation\",\n      \"journal\": \"Molecular and cellular biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — reconstitution-level reporter assay plus co-IP, multiple domains tested\",\n      \"pmids\": [\"10490596\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1999,\n      \"finding\": \"TEL (ETV6) functions as a transcriptional repressor by recruiting two distinct corepressor complexes: the central region of TEL recruits SMRT and mSin3A, while the HLH domain represses transcription through a corepressor-independent mechanism.\",\n      \"method\": \"GAL4 reporter assay, co-immunoprecipitation, deletion mutagenesis\",\n      \"journal\": \"Biochemical and biophysical research communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — multiple orthogonal methods, two distinct repression mechanisms identified\",\n      \"pmids\": [\"10544023\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1999,\n      \"finding\": \"UBC9 (a SUMO E2-conjugating enzyme) physically interacts with TEL specifically through its HLH domain in vitro and in vivo, and co-expression of UBC9 restores promoter activity repressed by TEL without inducing TEL degradation, indicating UBC9 modulates TEL transcriptional repressor activity.\",\n      \"method\": \"In vivo interaction assay (two-hybrid equivalent), co-immunoprecipitation, GAL4 reporter assay, mutagenesis of UBC9 catalytic residues\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — multiple orthogonal methods including mutagenesis and functional reporter\",\n      \"pmids\": [\"10377438\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1999,\n      \"finding\": \"ETV6 (TEL) represses the MCSFR proximal promoter in a DNA-binding-dependent manner, requiring the ETS DNA-binding domain; deletion of the HLH region reduces but does not abolish repression, and inhibition requires interaction with other promoter-bound proteins such as CBFA2B and C/EBPα.\",\n      \"method\": \"Reporter gene (luciferase) assays, deletion/mutational analysis of ETV6 and MCSFR promoter\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1 — in vitro reporter assay with mutagenesis; single study\",\n      \"pmids\": [\"9050885\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2000,\n      \"finding\": \"TEL (ETV6) recruits the nuclear receptor corepressor N-CoR through its central region, and this interaction is required for full transcriptional repression; TEL-AML1 fusion also binds N-CoR via the TEL central region retained in the fusion.\",\n      \"method\": \"Co-immunoprecipitation, deletion mutagenesis, reporter assays\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — co-IP plus functional reporter assay with domain mapping\",\n      \"pmids\": [\"11001911\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2000,\n      \"finding\": \"Fusion proteins containing the TEL oligomerization (pointed) domain fused to the kinase domains of JAK1, JAK2, JAK3, or TYK2 all confer cytokine-independent growth to Ba/F3 cells; STAT5 is the principal activated STAT in TEL-JAK2 and TEL-JAK1 cells, and a dominant-negative STAT5A blocks cytokine independence; TEL-JAK3 and TEL-TYK2 additionally activate STAT1 and STAT3.\",\n      \"method\": \"Ba/F3 growth factor independence assay, EMSA, dominant-negative STAT5 expression, gene expression analysis\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — reconstitution in hematopoietic cells, multiple JAK fusions tested, dominant-negative rescue\",\n      \"pmids\": [\"10706877\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2000,\n      \"finding\": \"TEL overexpression induces a G1 cell cycle arrest in multiple cell types and suppresses Ras-mediated transformation (colony formation in soft agar, tumor formation in nude mice); both the pointed domain and DNA-binding domain of TEL are required for these tumor suppressor phenotypes.\",\n      \"method\": \"Cell proliferation assays, soft agar colony assay, nude mouse tumor assay, TEL domain mutagenesis\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple orthogonal in vitro and in vivo assays with domain mapping\",\n      \"pmids\": [\"11077441\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2000,\n      \"finding\": \"TEL-JAK2 transgenic mice develop fatal T-cell leukemia with selective expansion of CD8+ T cells; the TEL-JAK2 protein is tyrosine-phosphorylated in leukemic tissue and activates STAT1 and STAT5 in vivo.\",\n      \"method\": \"Transgenic mouse model, flow cytometry, Western blot/phospho-analysis, TCR clonality analysis\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — in vivo transgenic model with biochemical STAT activation data\",\n      \"pmids\": [\"10845925\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2001,\n      \"finding\": \"TEL repression requires both the N-terminal pointed domain (which binds mSin3A) and a central repression domain (amino acids 268-303, which binds N-CoR); HDAC3, but not other HDACs, directly associates with the central region of TEL independently of N-CoR, and HDAC inhibition with trichostatin A impairs TEL-dependent repression and reverses TEL-induced cellular aggregation.\",\n      \"method\": \"Deletion mutagenesis, co-immunoprecipitation, ChIP (histone H3 acetylation at stromelysin-1 promoter), TSA treatment, reporter assay\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — ChIP plus co-IP plus functional pharmacological inhibition, multiple orthogonal methods\",\n      \"pmids\": [\"11439334\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2002,\n      \"finding\": \"ETV6-NTRK3 chimeric tyrosine kinase transforms murine mammary epithelial cells and forms tumors in nude mice that express epithelial antigens, establishing ETV6-NTRK3 as a dominantly acting oncogene in breast epithelial transformation; this fusion is present in 92% of human secretory breast carcinomas.\",\n      \"method\": \"Retroviral gene transfer, nude mouse tumor assay, immunohistochemistry, RT-PCR of patient tumors\",\n      \"journal\": \"Cancer cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — functional transformation assay in primary epithelial cells plus in vivo tumor formation\",\n      \"pmids\": [\"12450792\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2002,\n      \"finding\": \"TEL-Abl (ETV6-ABL1) fusion requires the TEL pointed domain oligomerization and ABL tyrosine kinase activity to induce myeloproliferative disease in mice; the fusion transforms multipotent hematopoietic progenitors capable of multilineage repopulation.\",\n      \"method\": \"Retroviral bone marrow transduction-transplantation model, domain mutagenesis, multilineage repopulation assays\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — in vivo mouse model with domain mutagenesis and progenitor characterization\",\n      \"pmids\": [\"12036890\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2002,\n      \"finding\": \"p38 MAP kinase directly phosphorylates TEL in vitro and in vivo at Ser22 (constitutive) and Ser257 (inducible); TEL binds p38 physically, and p38-dependent phosphorylation reduces TEL trans-repressional activity at ETS-binding sites.\",\n      \"method\": \"In vivo phosphorylation assay, in vitro kinase assay, reporter assay, co-immunoprecipitation, site-directed mutagenesis\",\n      \"journal\": \"Biochemical and biophysical research communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — in vitro kinase assay plus in vivo phosphorylation with mutagenesis and functional reporter\",\n      \"pmids\": [\"12435397\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"TEL represses the Bcl-XL promoter in a DNA-binding-dependent manner, reducing Bcl-XL mRNA and protein levels, and promotes apoptosis in serum-starved cells; this identifies Bcl-XL as a direct transcriptional target of TEL.\",\n      \"method\": \"Reporter gene assay, RT-PCR/Western blot for endogenous Bcl-XL, apoptosis assay, domain mutagenesis\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — functional reporter plus endogenous target validation, single study\",\n      \"pmids\": [\"12960174\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2004,\n      \"finding\": \"TEL-Syk fusion protein (from t(9;12)) is localized in the cytoplasm and constitutively activates PI3K/Akt, Vav, PLCγ2, MAPK, and STAT5 (independently of JAK2); the oligomerization (PNT) domain of TEL is required for all these signaling activities; TEL-Syk confers IL-3-independent growth to Ba/F3 cells.\",\n      \"method\": \"Immunofluorescence localization, Western blot of signaling pathway activation, Ba/F3 transformation assay, deletion mutagenesis (ΔPNTdomain)\",\n      \"journal\": \"Leukemia\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple signaling pathways probed with domain mutagenesis and functional transformation assay\",\n      \"pmids\": [\"14749700\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2004,\n      \"finding\": \"TEL/ETV6 functions as a STAT3-induced repressor of STAT3 activity; STAT3 activates ETV6 transcription, and ETV6 in turn represses STAT3 transcriptional activity through physical recruitment of ETV6 to STAT3 without requiring ETV6 DNA binding, forming a negative feedback loop.\",\n      \"method\": \"Microarray (STAT3 target identification), siRNA knockdown of TEL, reporter assay, co-immunoprecipitation, ETV6 overexpression\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2-3 — co-IP plus functional reporter plus siRNA, single study\",\n      \"pmids\": [\"15229229\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"The pointed domain of TEL/AML1, which recruits transcriptional repressors and directs oligomerization with TEL/AML1 or wild-type TEL, is essential for impaired B-cell differentiation and increased self-renewal of progenitors in vivo; another oligomerization domain cannot substitute for it.\",\n      \"method\": \"Bone marrow transplantation model, in vitro replating assays, domain substitution mutagenesis\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — in vivo mouse model with domain replacement, single study\",\n      \"pmids\": [\"16044150\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"The F-box protein Fbl6 binds TEL (ETV6) via its SAM (PNT) domain and stimulates ubiquitination of TEL leading to proteasomal degradation; sumoylation of Tel monomers (but not oligomers) sensitizes them for Fbl6-mediated proteasomal degradation, while Tel oligomers are stably sumoylated at K11 but more resistant to degradation.\",\n      \"method\": \"Co-immunoprecipitation, ubiquitination assay, proteasome inhibitor experiments, sumoylation assay\",\n      \"journal\": \"Molecular and cellular biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — biochemical ubiquitination and sumoylation assays with functional protein stability measurements\",\n      \"pmids\": [\"18426905\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"TEL (ETV6) is sumoylated at lysine 11 (K11); PIAS3 binds to TEL in the nucleus and stimulates K11 sumoylation; sumoylation of K11 inhibits TEL repression of gene expression by impeding TEL association with DNA; a TelM43 isoform lacking K11 is strongly repressive; PIAS3 can also augment TEL repressive function in a sumoylation-independent manner.\",\n      \"method\": \"Site-directed mutagenesis of K11, mass spectrometry identification of sumoylation site, co-immunoprecipitation with PIAS3, DNA-binding assay, reporter assay\",\n      \"journal\": \"Molecular and cellular biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — MS-identified sumoylation site, mutagenesis, biochemical DNA-binding and reporter assays\",\n      \"pmids\": [\"18212042\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"CBFβ heterodimerization with the Runt domain of AML1 in TEL-AML1 is essential for TEL-AML1's ability to promote self-renewal of B-cell precursors; Runt domain mutations that disrupt CBFβ binding without affecting DNA binding abrogate this function.\",\n      \"method\": \"Runt domain mutagenesis, B-cell precursor self-renewal assay in vitro, bone marrow reconstitution\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — domain mutagenesis with functional self-renewal readout, single study\",\n      \"pmids\": [\"19179469\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"ETV6-NTRK3-driven transformation of mammary epithelial cells requires the IGF1R/INSR signaling axis; PI3K-Akt is activated in an IGF1- or insulin-dependent manner downstream of ETV6-NTRK3, and dual IGF1R/INSR inhibitors block EN transformation in vitro and tumor growth in vivo.\",\n      \"method\": \"3D Matrigel culture, tumor formation assay, pharmacological inhibition (BMS-536924, BMS-754807), Western blot of PI3K-Akt signaling\",\n      \"journal\": \"Cancer research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple inhibitors, in vitro and in vivo tumor assays, pathway analysis\",\n      \"pmids\": [\"21148487\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"ETV6 DNA binding is autoinhibited by two C-terminal helices (H4 and H5) that sterically block the DNA-binding interface of the ETS domain; these helices are only marginally stable and the CID dampens millisecond-timescale motions of the ETS domain critical for specific DNA recognition.\",\n      \"method\": \"NMR spectroscopy (amide hydrogen exchange, 15N relaxation measurements), structural analysis of ETS domain + CID\",\n      \"journal\": \"Journal of molecular biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — NMR structure with dynamic measurements, mechanistic characterization of autoinhibition\",\n      \"pmids\": [\"22584210\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"Germline missense mutations in the ETV6 ETS DNA-binding domain (p.Arg369Gln, p.Arg399Cys) and the internal linker domain (p.Pro214Leu) abrogate DNA binding, alter subcellular localization (cytoplasmic mislocalization of mutant and endogenous ETV6), decrease transcriptional repression in a dominant-negative fashion, and impair megakaryocyte maturation and hematopoiesis.\",\n      \"method\": \"Whole-exome sequencing, functional reporter assays, subcellular localization by microscopy, megakaryocyte differentiation assay\",\n      \"journal\": \"Nature genetics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple functional assays on natural human variants with dominant-negative mechanism characterized\",\n      \"pmids\": [\"25581430\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"ETV6 mutations (p.Pro214Leu in central domain; p.Arg418Gly in DNA-binding domain) cause aberrant cytoplasmic localization of both mutant and endogenous ETV6, decreased transcriptional repression, and altered megakaryocyte maturation.\",\n      \"method\": \"Whole-exome sequencing, subcellular localization microscopy, transcriptional reporter assay, megakaryocyte maturation assay\",\n      \"journal\": \"Nature genetics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple orthogonal functional assays with natural human variants\",\n      \"pmids\": [\"25807284\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"Germline ETV6 mutations (p.L349P, p.N385fs) impair nuclear localization of ETV6 and significantly reduce its ability to regulate transcription of ETV6 target genes, establishing a dominant-negative mechanism for leukemia predisposition.\",\n      \"method\": \"Enforced expression of ETV6 mutants, subcellular localization assay, transcriptional target gene reporter assay\",\n      \"journal\": \"PLoS genetics\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — localization and functional assay but single study\",\n      \"pmids\": [\"26102509\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"ETV6-RUNX1 fusion drives widespread repression of RUNX1 motif-containing enhancers at target gene loci, including super-enhancers of the CD19+/CD20+ B-cell lineage; this repression depends on the wild-type DNA-binding Runt domain of RUNX1 and results in downregulation of genes involved in B-cell signaling and adhesion.\",\n      \"method\": \"Global run-on sequencing (GRO-seq), ChIP-seq, enhancer RNA profiling, Runt domain mutant analysis\",\n      \"journal\": \"Genome research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — genome-wide mechanistic study with domain mutagenesis validation\",\n      \"pmids\": [\"27620872\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"ETV6 and ETV3 transcriptional repressors control human monocyte differentiation into dendritic cells by directly repressing MAFB expression (thus suppressing macrophage fate); in vivo, monocyte-specific Etv6 deletion causes spontaneous IFN-stimulated gene expression and impairs mo-DC differentiation during inflammation.\",\n      \"method\": \"Conditional Etv6 knockout in monocytes, gene expression analysis, MAFB ChIP, DC differentiation assay, EAE model\",\n      \"journal\": \"Nature immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — conditional KO with defined molecular target (MAFB) and in vivo phenotype\",\n      \"pmids\": [\"36543959\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"Etv6 deletion in the bone marrow abolishes CD8α expression on cDC1 conventional dendritic cells in vivo and impairs cDC1-specific gene expression and chromatin signatures while causing aberrant up-regulation of pDC-specific signatures; DC-specific Etv6 deletion impairs CD8+ T-cell cross-priming and tumor-specific T-cell responses.\",\n      \"method\": \"Bone marrow-specific Etv6 deletion, flow cytometry, gene expression profiling, chromatin accessibility (ATAC-seq-related), cross-priming functional assay\",\n      \"journal\": \"The Journal of experimental medicine\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — conditional KO with multiple orthogonal functional and epigenomic readouts\",\n      \"pmids\": [\"30087163\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"In Xenopus, Etv6 positively regulates vegfa expression during blood stem cell development through two mechanisms: (1) directly repressing the transcriptional repressor foxo3 (preventing Foxo3 from binding and repressing the vegfa promoter — a double-negative gate); (2) directly activating klf4, which then recruits Etv6 to the vegfa promoter to activate its expression (feed-forward loop).\",\n      \"method\": \"Xenopus embryo loss-of-function (morpholino), ChIP, reporter assay, rescue experiments\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — ChIP and functional epistasis in Xenopus model, mechanistically detailed but single organism\",\n      \"pmids\": [\"30842454\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"Germline ETV6 variants linked to ALL predisposition show impaired transcription repressor activity, loss of DNA binding, and altered nuclear localization; missense variants retain dimerization with wild-type ETV6 exerting dominant-negative effects; ATAC-seq profiling identified specific ETV6 genomic targets relevant to tumor suppressor activity.\",\n      \"method\": \"Functional reporter assay, DNA-binding assay, nuclear localization microscopy, dimerization assay, ATAC-seq, whole-transcriptome and whole-genome sequencing\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — comprehensive multi-method functional characterization of 22 variants with epigenomic profiling\",\n      \"pmids\": [\"32693409\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"ETV6 acts as a transcriptional repressor that competes with EWS-FLI1 for binding to select DNA elements enriched for short GGAA repeat sequences; upon ETV6 inactivation, EWS-FLI1 hyper-activates these cis-elements promoting mesenchymal differentiation (via SOX11); a dominant-interfering ETV6 peptide phenocopies ETV6 loss and suppresses Ewing sarcoma growth in vivo.\",\n      \"method\": \"CRISPR domain-focused screen, ChIP-seq, ATAC-seq, biochemical competition assay, dominant-interfering peptide, in vivo xenograft\",\n      \"journal\": \"Nature cell biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — epigenomics, biochemical competition, and in vivo functional assays in one study\",\n      \"pmids\": [\"36658219\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"ETV6 functions as an epigenetic gatekeeper by directly binding GGAA tandem repeat enhancers, repressing their histone acetylation, and downregulating adjacent genes including EPOR; in ETV6-deficient B-ALL, the ETS factor ERG occupies these GGAA microsatellite enhancers and drives aberrant gene activation.\",\n      \"method\": \"ChIP-seq for ETV6 binding at GGAA repeats, histone acetylation ChIP, ERG knockdown, ETV6 restoration experiments\",\n      \"journal\": \"Blood cancer discovery\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — multiple epigenomic and functional assays defining ETV6's molecular gatekeeper mechanism at GGAA enhancers\",\n      \"pmids\": [\"36350827\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"ETV6 (TEL) is an ETS-family transcriptional repressor that binds GGAA-containing DNA elements through its autoinhibited ETS domain (regulated by C-terminal helices and by PTMs including p38-mediated phosphorylation at Ser22/Ser257 and PIAS3-mediated sumoylation at K11); it recruits corepressor complexes (mSin3A via the pointed/PNT domain, N-CoR and HDAC3 via a central repression domain) to silence target genes including Bcl-XL and EPOR-activating microsatellite enhancers, while its PNT/HLH domain drives homo-oligomerization and, when fused to kinase domains (NTRK3, JAK2, ABL1, etc.) by chromosomal translocations, mediates constitutive kinase activation and oncogenic transformation; in normal hematopoiesis ETV6 is specifically required for bone marrow hematopoietic engraftment, megakaryocyte maturation, and dendritic cell lineage commitment, and germline loss-of-function mutations cause dominant-negative cytoplasmic mislocalization and DNA-binding defects leading to thrombocytopenia and leukemia predisposition.\"\n}\n```","stage2_raw":"```json\n{\n  \"mechanistic_narrative\": \"ETV6 (TEL) is an ETS-family transcriptional repressor that governs hematopoietic stem cell engraftment, megakaryocyte maturation, and dendritic cell lineage commitment, and whose disruption by chromosomal translocation or germline mutation drives leukemia and solid tumor pathogenesis. ETV6 binds GGAA-containing DNA elements through an autoinhibited ETS domain regulated by marginally stable C-terminal helices [PMID:22584210], and represses target genes—including Bcl-XL, MAFB, and GGAA-microsatellite enhancers controlling EPOR—by recruiting mSin3A via its pointed/PNT domain and N-CoR/HDAC3 via a central repression domain [PMID:10490596, PMID:11439334, PMID:36350827]. Its activity is modulated by p38-mediated phosphorylation at Ser22/Ser257, PIAS3-mediated sumoylation at K11 (which impairs DNA binding), and Fbl6-directed ubiquitin-proteasomal degradation of sumoylated monomers [PMID:12435397, PMID:18212042, PMID:18426905]. Germline loss-of-function mutations in ETV6 cause dominant-negative cytoplasmic mislocalization and defective transcriptional repression, resulting in thrombocytopenia and predisposition to acute lymphoblastic leukemia, while the PNT domain's oligomerization capacity is co-opted by chromosomal translocations that constitutively activate partner kinases such as JAK2, NTRK3, and ABL1 [PMID:25581430, PMID:9360930, PMID:9462753].\",\n  \"teleology\": [\n    {\n      \"year\": 1997,\n      \"claim\": \"Establishing TEL as a nuclear phosphoprotein ETS-family DNA-binding factor resolved the basic biochemical identity of the ETV6 gene product, showing it recognizes canonical ETS sites and exists as two phosphorylated isoforms.\",\n      \"evidence\": \"Western blot, immunofluorescence, and EMSA on murine TEL cDNA products\",\n      \"pmids\": [\"9018121\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Phosphorylation sites and responsible kinases not identified\", \"Endogenous target genes unknown\"]\n    },\n    {\n      \"year\": 1998,\n      \"claim\": \"Discovery that the TEL pointed/HLH domain drives constitutive kinase activation when fused to JAK2 or NTRK3 established the general principle by which ETV6 translocations cause oncogenesis—oligomerization-dependent kinase autophosphorylation.\",\n      \"evidence\": \"Cloning of t(9;12) TEL-JAK2 and t(12;15) TEL-NTRK3 fusions, in vitro kinase assay, Ba/F3 cytokine-independence assay\",\n      \"pmids\": [\"9360930\", \"9462753\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Downstream signaling pathways not yet mapped for all fusions\", \"Whether oligomerization suffices or additional PNT-domain functions contribute was unresolved\"]\n    },\n    {\n      \"year\": 1998,\n      \"claim\": \"Knockout chimera studies demonstrated that ETV6 is specifically required for bone marrow hematopoiesis—the first transcription factor shown to be dispensable for yolk sac/fetal liver blood formation but essential for marrow engraftment.\",\n      \"evidence\": \"TEL-/- ES cell chimeras, lineage analysis of hematopoietic organs in mice\",\n      \"pmids\": [\"9694803\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct transcriptional targets mediating engraftment not identified\", \"Whether ETV6 acts cell-autonomously in HSCs vs. niche cells was unresolved\"]\n    },\n    {\n      \"year\": 1999,\n      \"claim\": \"Identification of mSin3A, SMRT, and UBC9 as pointed-domain and central-region interactors revealed that ETV6 represses transcription through recruitment of corepressor/HDAC complexes and is post-translationally regulated by the SUMO conjugation machinery.\",\n      \"evidence\": \"Co-immunoprecipitation, GAL4 reporter assays, deletion mutagenesis, UBC9 interaction assay\",\n      \"pmids\": [\"10490596\", \"10544023\", \"10377438\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Identity of HDAC isoform in the complex not yet determined\", \"Sumoylation site not mapped\"]\n    },\n    {\n      \"year\": 2000,\n      \"claim\": \"Mapping N-CoR recruitment to ETV6's central domain, demonstrating STAT5 as the critical downstream effector of TEL-JAK fusions, and showing TEL overexpression causes G1 arrest and suppresses Ras transformation collectively defined ETV6 as both a tumor suppressor and (when translocated) an oncogene activating JAK-STAT signaling.\",\n      \"evidence\": \"Co-IP/reporter assays for N-CoR, Ba/F3 assays with dominant-negative STAT5, soft agar and nude mouse assays for tumor suppression\",\n      \"pmids\": [\"11001911\", \"10706877\", \"11077441\", \"10845925\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct target genes mediating G1 arrest not identified\", \"Whether N-CoR and mSin3A act in the same or distinct complexes on chromatin was unclear\"]\n    },\n    {\n      \"year\": 2001,\n      \"claim\": \"Demonstration that HDAC3 directly binds ETV6's central region independently of N-CoR, and that HDAC inhibition reverses ETV6-dependent repression and cellular phenotypes, established the chromatin-modifying mechanism underlying ETV6 target gene silencing.\",\n      \"evidence\": \"Co-IP, ChIP for histone H3 acetylation at stromelysin-1 promoter, trichostatin A treatment\",\n      \"pmids\": [\"11439334\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Genome-wide target identification not performed\", \"Whether HDAC3 is required at all ETV6-bound loci was unknown\"]\n    },\n    {\n      \"year\": 2002,\n      \"claim\": \"Identification of p38 MAPK as a direct ETV6 kinase phosphorylating Ser22 and Ser257 provided the first signal-responsive regulatory mechanism controlling ETV6 repressor activity.\",\n      \"evidence\": \"In vitro kinase assay, in vivo phosphorylation, site-directed mutagenesis, reporter assay\",\n      \"pmids\": [\"12435397\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Physiological stimuli triggering p38-ETV6 axis not defined\", \"Functional consequence of each individual phosphosite not fully dissected\"]\n    },\n    {\n      \"year\": 2008,\n      \"claim\": \"Mapping sumoylation to K11 by mass spectrometry and showing that PIAS3-catalyzed sumoylation impairs ETV6 DNA binding, while Fbl6-mediated ubiquitination selectively degrades sumoylated monomers, revealed a SUMO–ubiquitin switch governing ETV6 protein stability and activity.\",\n      \"evidence\": \"Mass spectrometry, sumoylation and ubiquitination assays, proteasome inhibitor experiments, DNA-binding assays\",\n      \"pmids\": [\"18212042\", \"18426905\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether this switch operates in primary hematopoietic cells in vivo is untested\", \"Structural basis of how K11 sumoylation blocks DNA binding not resolved\"]\n    },\n    {\n      \"year\": 2012,\n      \"claim\": \"NMR analysis revealed that C-terminal helices H4/H5 autoinhibit the ETS domain by sterically blocking DNA contact and dampening millisecond dynamics required for DNA recognition, explaining how ETV6 DNA binding is kept in check in the absence of activating signals.\",\n      \"evidence\": \"NMR amide hydrogen exchange and 15N relaxation measurements on ETS domain ± CID\",\n      \"pmids\": [\"22584210\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"What relieves autoinhibition in vivo (partner protein, PTM, or oligomerization) is unknown\", \"No full-length ETV6 structure available\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"Discovery that germline ETV6 mutations cause dominant-negative cytoplasmic mislocalization, impaired DNA binding, and defective megakaryocyte maturation linked ETV6 loss-of-function to inherited thrombocytopenia and leukemia predisposition in humans.\",\n      \"evidence\": \"Whole-exome sequencing of affected families, functional reporter and localization assays, megakaryocyte differentiation assays\",\n      \"pmids\": [\"25581430\", \"25807284\", \"26102509\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Mechanism of cytoplasmic mislocalization by linker-domain mutations not structurally explained\", \"Penetrance and modifier genes for leukemia progression unknown\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"Conditional knockout studies established ETV6 as a lineage-determining factor for dendritic cells: it represses MAFB to permit monocyte-to-DC differentiation and maintains cDC1 identity including CD8α expression and cross-priming capacity.\",\n      \"evidence\": \"Monocyte- and DC-specific Etv6 conditional KO mice, MAFB ChIP, ATAC-seq, cross-priming assays, EAE model\",\n      \"pmids\": [\"36543959\", \"30087163\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether ETV6 cooperates with ETV3 at all DC-specific loci is not resolved\", \"Direct ETV6 chromatin targets in cDC1 not comprehensively mapped\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"Epigenomic studies revealed that ETV6 functions as a gatekeeper at GGAA tandem-repeat microsatellite enhancers, directly binding these elements to maintain repressive histone marks; loss of ETV6 permits replacement by ERG or EWS-FLI1, hyper-activating adjacent genes including EPOR and SOX11.\",\n      \"evidence\": \"ChIP-seq for ETV6/ERG at GGAA repeats, histone acetylation ChIP, CRISPR screen, dominant-interfering peptide, xenograft assays\",\n      \"pmids\": [\"36658219\", \"36350827\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether ETV6 competes with all ETS factors at GGAA repeats or selectively with ERG/FLI1 is unresolved\", \"Structural basis of ETV6 preference for tandem GGAA repeats not determined\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"Key unresolved questions include the full-length structure of ETV6, the mechanism by which autoinhibition is relieved in vivo, the comprehensive identification of direct ETV6 target genes in HSCs mediating bone marrow engraftment, and how ETV6 loss cooperates with secondary hits to drive leukemic transformation.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Low\",\n      \"gaps\": [\"No full-length structural model\", \"In vivo mechanism of autoinhibition relief unknown\", \"Cooperating genetic events for leukemia transformation not systematically defined\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0003677\", \"supporting_discovery_ids\": [0, 7, 24, 33, 34]},\n      {\"term_id\": \"GO:0140110\", \"supporting_discovery_ids\": [4, 5, 7, 8, 12, 16, 18, 25, 29, 32, 34]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005634\", \"supporting_discovery_ids\": [0, 21, 25, 26, 27]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"GO:0005634\", \"supporting_discovery_ids\": []},\n      {\"term_id\": \"R-HSA-74160\", \"supporting_discovery_ids\": [4, 5, 7, 8, 12, 16, 29, 34]},\n      {\"term_id\": \"R-HSA-4839726\", \"supporting_discovery_ids\": [12, 34]},\n      {\"term_id\": \"R-HSA-1266738\", \"supporting_discovery_ids\": [3, 25, 29, 30]},\n      {\"term_id\": \"R-HSA-168256\", \"supporting_discovery_ids\": [29, 30]},\n      {\"term_id\": \"R-HSA-1643685\", \"supporting_discovery_ids\": [1, 2, 13, 14, 25, 32, 33]}\n    ],\n    \"complexes\": [\n      \"N-CoR/HDAC3 corepressor complex\",\n      \"mSin3A corepressor complex\"\n    ],\n    \"partners\": [\n      \"NCOR1\",\n      \"HDAC3\",\n      \"SIN3A\",\n      \"PIAS3\",\n      \"UBE2I\",\n      \"FBXL6\",\n      \"MAPK14\",\n      \"STAT3\"\n    ],\n    \"other_free_text\": []\n  }\n}\n```"}